Shares of Organogenesis Holdings Inc. (ORGO) fell 5.12% in Friday's intraday trading, following the release of a new local coverage determination (LCD) by the Centers for Medicare & Medicaid Services (CMS) regarding skin substitute grafts and cellular tissue-based products for treating diabetic foot ulcers and venous leg ulcers.
While Organogenesis welcomed the evidence-based approach and the inclusion of its NuShield product in the covered list, investors appear concerned about the potential impact of the new policy on reimbursement levels and future revenue.
The company acknowledged that the LCD decision could affect coverage and reimbursement levels for its products, which has been a key risk factor in the past. As Organogenesis navigates this new policy landscape, investors will closely monitor its ability to maintain profitability and growth momentum.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。